AIM: Polycystic ovary syndrome (PCOS) is a multifactorial pathology affecting 
5-10% of the female population. Usually occurs with oligo/amenorrhea, 
anovulation, hirsutism, polycystic ovaries. Hyperinsulinemia associated with 
insulin resistance has been causally linked to all features of the syndrome. It 
has been demonstrated that by reducing hyperinsulinemia, in particular with the 
administration of metformin, insulin-lowering agents might improve endocrine and 
reproductive abnormalities in PCOS patients.
METHODS: A new molecule with insulin-sensitizing properties, myo-inositol, has 
recently been successfully administered in women with PCOS. New associations 
between natural substances like myo-inositol and other components have been 
proposed to improve the therapeutical efficacy. Among these substances, the 
monacolin K, a natural statin appeared to have important actions in cholesterol 
synthesis. In this article we study the effect of inositol alone and the 
association between myo-inositol and monacolinin K in the treatment of PCOS with 
insulin resistance, menstrual irregularities and hirsutism.
RESULTS AND CONCLUSION: The results of this study demonstrated a good efficacy 
of both treatments, although in the group treated with the combination of 
myo-inositol/monacolin K improvement in lipids and hyperandrogenism were 
significantly better.